Community pharmacy's role in menopause care has expanded significantly in the last four years. The HRT prepayment certificate, introduced in April 2023, has changed how patients pay for long-term HRT in England. The 2022 reclassification of low-dose vaginal oestrogen to a pharmacy-only medicine has moved a commonly needed local therapy out of the prescription-only category for women aged 50 and over. And NICE NG23 continues to frame HRT as the first-line treatment for vasomotor symptoms of menopause.

This article summarises where community pharmacy now fits in menopause care: the routine counter conversations, the continuity-of-supply role, and the lifestyle advice supported by UK guidance.

HRT, briefly

Hormone replacement therapy is oestrogen alone for women who have had a hysterectomy, or combined oestrogen plus a progestogen for women with an intact uterus (the progestogen protects the endometrium). NICE NG23 recommends HRT as the most effective treatment for vasomotor symptoms (hot flushes, night sweats) and supports its role in managing other symptoms and in bone health considerations.

HRT is available in multiple delivery routes:

The HRT prepayment certificate

Introduced in April 2023 by NHSBSA, the HRT PPC costs a flat annual fee and covers most NHS HRT prescriptions for the full year. For patients on long-term HRT, the PPC typically saves several single-prescription-charge equivalents over 12 months.

Counter points:

• The PPC covers HRT items only — not analgesia, antidepressants, other menopause-related medicines (unless they are themselves an HRT item), or general prescriptions.
• It is purchased separately from the general NHS PPC.
• It runs for 12 months from the date of purchase.
• Patients exempt from NHS prescription charges do not need to buy the PPC.

Pharmacies have a useful role in flagging the HRT PPC to patients who are paying standard charges for an HRT item each month.

Reclassified vaginal oestrogen

In September 2022 the MHRA reclassified Gina 10 (low-dose vaginal estradiol 10 microgram tablet) from prescription-only (POM) to pharmacy-only (P) medicine, under specific criteria:

• Women aged 50 years and over.
• Symptoms of vaginal atrophy consistent with postmenopausal presentation (vaginal dryness, irritation, dyspareunia).
• At least one year since the last menstrual period.
• No unexplained vaginal bleeding.
• No contraindication to topical oestrogen (including oestrogen-sensitive cancer history).
• Not already using another oestrogen preparation without clinical supervision.

Supply is via a structured consultation, with the pharmacist using an inclusion and exclusion framework before recommending. A maximum 12-month course is permitted via the pharmacy route before review, reflecting the expectation that longer-term use be medically supervised.

For many women this is the first time a menopause-related therapy has been accessible without a prescription, and for community pharmacy it is one of the more clinically substantive P-medicine consultations. Training and a clear SOP are essential for pharmacies choosing to stock Gina.

The supply-continuity role

Supply interruptions have been a recurrent feature of UK HRT over the last five years — patches in particular have been affected by intermittent manufacturing and distribution pressures. Pharmacies have played a quiet role in:

• Identifying equivalent alternative products when the usual brand is unavailable.
• Supplying a Serious Shortage Protocol (SSP) alternative when one is in force for a specific HRT preparation.
• Contacting prescribers to arrange a clinically appropriate switch where SSPs are not available.

Patients are reasonably upset when a long-standing regimen has to change because of supply. A clear, calm explanation of what is being substituted and why is a substantial part of the consultation.

Lifestyle and symptom-management advice

NICE NG23 and NICE CKS support a package of lifestyle advice that sits alongside, or in place of, HRT:

• Lifestyle measures: regular exercise, weight management, minimising alcohol, avoiding smoking.
• Cognitive behavioural therapy has an evidence base for vasomotor symptoms and sleep disturbance.
• Vaginal moisturisers and lubricants (non-hormonal) for genitourinary symptoms, either alongside vaginal oestrogen or in patients who do not want hormonal treatment.
• Calcium and vitamin D where dietary intake is inadequate or bone health is a concern.
• Sleep hygiene and layered clothing for night sweats — small practical points often appreciated at the counter.

Herbal products (black cohosh, red clover, soya isoflavones, St John's wort) are used by some patients. NICE NG23 acknowledges that some women find these helpful but notes variable evidence quality, variable product quality, and potential interactions — particularly St John's wort, which interacts with many medications including HRT, SSRIs, warfarin and contraceptives. Pharmacy counter advice should flag the interaction risk explicitly.

Referral points

Community pharmacy is a starting point, not the end of the pathway. Referral to the GP is indicated where:

• Symptoms are not adequately controlled by initial self-care or OTC products.
• The patient is under 45 and experiencing menopausal symptoms (possible premature ovarian insufficiency — requires clinical assessment).
• Unexplained vaginal bleeding occurs, especially post-menopause.
• HRT is being considered and the woman is not currently under the care of a prescriber.
• There are complex comorbidities (breast cancer history, VTE history, liver disease, migraine with aura) relevant to HRT selection.
• Mood, cognitive or severe sleep symptoms require broader assessment.

What community pharmacy can and can't do

Pharmacy can: dispense HRT, explain formulations, manage the PPC, supply Gina to eligible women under its P-medicine SOP, offer lifestyle advice, flag interactions, support supply continuity, and refer when care needs to escalate.

Pharmacy First does not include a menopause-specific clinical pathway; menopause care is delivered through general practice and, increasingly, dedicated menopause services. Pharmacist independent prescribers in primary care networks are increasingly involved in menopause reviews, and that is a growing part of the clinical pharmacist role.

Caveats

This article summarises NICE NG23, NICE CKS, MHRA reclassification documentation and NHSBSA PPC guidance current to April 2026. Individual HRT decisions should be made with the prescribing clinician.

Sources

• NICE NG23 — Menopause: diagnosis and management
• NICE Clinical Knowledge Summaries — Menopause
• MHRA — Reclassification of Gina 10 (vaginal estradiol) to pharmacy-only medicine
• NHSBSA — HRT prepayment certificate

Find a community pharmacy that stocks Gina or offers menopause support via PharmSee's pharmacy finder.